We performed a review of the literature to determine whether the dipeptidyl peptidase-4
inhibitors (DPP4-I) may have the capability to directly and positively influence diabetic …

The introduction of dipeptidyl peptidase 4 (DPP4) inhibitors for the treatment of Type 2
diabetes acknowledges the fundamental importance of incretin hormones in the regulation …

In various embodiments, the present invention provides methods of reducing the risk of a
cardiovascular event in a subject on statin therapy and, in particular, a method of reducing …

Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique
form of disease management for persons with type 2 diabetes mellitus. The aim of this …

US9814733B2 - Compositions comprising EPA and obeticholic acid and methods of use
thereof - Google Patents US9814733B2 - Compositions comprising EPA and obeticholic …

The present invention relates to, inter alia, pharmaceutical compositions comprising EPA
and one or more cardiovascular agents, and to therapeutic methods for treating various …

In various embodiments, the present invention provides methods of reducing the risk of a
cardiovascular event in a subject on statin therapy and, in particular, a method of reducing …

Atherosclerosis is the leading cause of death worldwide, especially in patients with type 2
diabetes mellitus (T2D). GLP-1 receptor agonists and DPP-4 inhibitors were demonstrated …

In various embodiments, the present invention provides methods of reducing the risk of a
cardiovascular event in a subject on statin therapy and, in particular, a method of reducing …

US9624492B2 - Compositions comprising eicosapentaenoic acid and mipomersen and
methods of use thereof - Google Patents US9624492B2 - Compositions comprising …